Please login to the form below

Not currently logged in
Email:
Password:

AZ and Inserm collaborate on diabetes and kidney disease

Three-year partnership will look at new therapeutic approaches

AstraZeneca AZ headquarters London UK 

AstraZeneca and the French National Institute of Health and Medical Research (Inserm) have entered a collaboration to investigate new therapeutic approaches to type 2 diabetes and chronic kidney disease.

The partnership aims to advance the understanding of biological mechanisms that come with the conditions and develop new treatments based on the findings.

Professor Christian Boitard, director of the Inserm institute for physiopathology, metabolism and nutrition, said: “This collaboration is focusing our efforts in beta cells, mineralocorticoid receptor and lipids handling by tissues. 

“Combining the AstraZeneca and Inserm scientists, expertise and platforms represents a great opportunity for advancing research in these important fields, with the operational support of Inserm Transfert teams.”

The combined team will explore pharmacological ways to prevent the release of lipids into the circulation, normalise fat deposition and increase insulin sensitivity in peripheral tissues.

AZ and Inserm will also explore the mineralocorticoid receptor (MR) activity as a route to treating chronic kidney disease to better understand its complexities as a potential treatment.

Dr Raphael Scharfmann at Inserm will additionally develop models of human beta cells that have lost their ability to produce and release insulin to better understand the biology of this effect and how it can be corrected with treatment.

Marcus Schindler, head of cardiovascular and metabolic diseases innovative medicines unit at AZ, commented: “Over the last few years AstraZeneca has been focusing on pioneering research into cardiovascular and metabolic disease. 

“By joining forces with Professors Langin, Jaisser and Scharfmann and their eminent research groups at Inserm, we strengthen further this ambition because their focus represents an ideal fit with our research strategy.”

Earlier this year, AZ teamed up with Harvard University as part of a five-year project to discover new treatments for diabetes.

Article by
Kirstie Pickering

18th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics